
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances, a designation, a priority review, an NDA acceptance, and the lifting of a clinical trial hold.



